Endothelin-1 Enhances Corneal Fibronectin Deposition and Promotes Corneal Epithelial Wound Healing after Photorefractive Keratectomy in Rabbits  by Lai, Yu-Hung et al.
Kaohsiung J Med Sci May 2008 • Vol 24 • No 5254
© 2008 Elsevier. All rights reserved.
After corneal excimer laser refractive surgery, kerato-
cytes proliferate and produce extracellular matrixes
that may result in corneal haze and regression of laser
effect [1,2]. Corticosteroid eye drops are commonly
used to prevent such complications after refractive sur-
gery. However, corticosteroid-related complications
such as glaucoma or cataracts prompted us to look
for alternatives to control keratocyte activity.
Endothelin-1 (ET1) is a potent vasoconstrictor [3,4].
Endothelin-like immunoreactivity is found not only
in vessels but also in ocular tissues [5,6]. In addition,
ET1 can promote rabbit corneal epithelial wound heal-
ing [7,8]. Since the epithelial defect is the major source
of ocular discomfort and pain after PRK [9,10], by
giving ET1 eye drops, we may reduce the duration of
pain in patients who receive PRK treatment through
the promotion of epithelial healing rate. We found
that ET1 has an inhibitory effect on porcine corneal
keratocytes [11]. With regard to the above-mentioned
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The objective was to study the effects of endothelin-1 (ET1) on corneal wound healing after 
photorefractive keratectomy (PRK) in rabbit corneas. Following PRK, 18 New Zealand white rabbits
were treated with ET1 in the right eyes and with phosphate-buffered salt solution (PBS) in the left
eyes. Corneal epithelial wound size, corneal haze and corneal thickness were recorded. Corneal
extracellular matrixes, including collagen types 3, 4 and 7, chondroitin sulfate and fibronectin,
were investigated using immunohistochemistry study. ET1 increased the rate of healing of corneal
epithelial wounds in rabbits. Anti-fibronectin fluorescence was present at week 12 and week 24 in
ET1-treated eyes but not in the control eyes. There were no significant differences in corneal haze,
corneal thickness and changes in other extracellular matrixes between ET1- and PBS-treated eyes.
ET1 can enhance the deposition of fibronectin in corneal stroma and promote corneal epithelial
wound healing after PRK. The increase in fibronectin probably explains the increased healing rate
of corneal epithelial wounds.
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keratocyte proliferation and related extracellular matrix
deposition, it would probably also be beneficial to PRK
patients if ET1 inhibited the adverse effect of kerato-
cytes in corneal stromal wound healing [1,2]. In this
study, we investigated the effects of ET1 on rabbit
corneas, including the rate of epithelialization, haze
and extracellular matrixes after PRK.
MATERIALS AND METHODS
Animals
All animals were treated in accordance with the tenets
of the ARVO Statement for the Use of Animals in Oph-
thalmic and Vision Research. Eighteen New Zealand
white rabbits, weighing between 2 kg and 2.5 kg, were
used in the study. The rabbits were divided into groups
according to the time of sacrifice: six rabbits in the 
4-week group, six in the 12-week group, and six in the
24-week group. All rabbits were anesthetized before
surgery with intramuscular injections of 30 mg/kg
ketamine hydrochloride (Parke, Davis & Co., Detroit,
MI, USA) and 5 mg/kg xylazine (Miles Inc., Shawnee
Mission, KS, USA), combined with topical anesthesia
of proparacaine hydrochloride 0.5% (Alcon, Rijksweg,
Puurs, Belgium).
Excimer laser and medications
We removed the corneal epithelium with excimer laser
(Schwind Keratom MultiScan Excimerlaser; Schwind
eye-tech-solutions, Kleinostheim, Germany) in PTK
mode with an ablation depth of 60 μm [12]. The diam-
eter of the ablation zone was 7 mm. Following PTK,
PRK (−8 D and 5 mm in diameter) was performed on
both eyes. Immediately after PRK, gentamicin sulfate
0.3% eye drops (Shionogi, Japan) were applied. In
addition, ET1 10–7 M eye drops (Sigma Chemicals, St
Louis, MO, USA) were applied to the right eyes, and
phosphate-buffered salt solution (PBS) to the left eyes.
After the operation, gentamicin sulfate 0.3% eye drops
and ET1 10–7 M eye drops were applied five times a
day for 7 days to the right eyes, and gentamicin sulfate
and PBS to the left (which served as controls).
Corneal epithelial wound healing rate,
corneal haze and corneal thickness study
Rabbit eyes were examined every 12 hours until corneal
epithelialization was complete. To observe the epithe-
lial defect, we used fluorescent staining. The longest
horizontal (Lh) and longest vertical (Lv) lengths were
measured, and the area of corneal epithelial defect
was approximately calculated as Lh × Lv [13]. We cal-
culated the average values of the results of each time
point, and the difference between the two eyes was
analyzed by paired t test. We observed corneal haze
at 2, 4, 8, 12, 18 and 24 weeks after PRK. Corneal haze
was defined as the following: Grade 1, haze not in-
terfering with visibility of iris details; grade 2, mild
obscuration of iris and lens; grade 3, moderate obscu-
ration of iris and lens; and grade 4, completely opaque
stroma in the area of ablation [14]. The result of corneal
haze was evaluated by signed rank test. Central corneal
ultrasound pachymetry was performed at weeks 4,
12 and 24. The results were analyzed by paired t test
and signed rank test.
Immunohistochemistry study of corneal
extracellular matrixes
Corneas were excised after PRK at scheduled time
points: week 4, week 12 and week 24. Rabbits were
anesthetized with ketamine 30 mg/kg and xylazine
5 mg/kg, and then euthanized by an intracardiac in-
jection of an overdose of ketamine. The corneas were
immediately excised and embedded in OCT com-
pound (Optimal Cutting Temperature, Tissue-Tek
OCT compound; SAKURA Co., Japan). The immuno-
histochemistry procedures are briefly described as
follows: after being embedded in OCT compound in
a chamber with a temperature of −40°C for 2 hours,
the corneas were sectioned into 8-μm slices using
Cryostat (Bright OTF Cryostat, Huntingdon, England).
The samples were dipped in 0°C acetone for 1 minute.
We added 10% normal goat serum (Zymed, San
Francisco, CA, USA) to the samples, placed them in
room temperature for 30 minutes, then washed them
with PBS. The following primary antibodies (with con-
centrations shown in parentheses) were added: anti-
collagen type 3 (1:4,000), anti-collagen type 4 (1:500),
anti-collagen type 7 (1:1,000), anti-chondroitin sulfate
(1:200) (Sigma Chemicals), and antibody to fibronectin
(not diluted) (Zymed, San Francisco, CA, USA). They
were incubated in a 37°C moist chamber for 1 hour
and then washed with PBS. A secondary antibody,
fluorescein-isothiocyanate (FITC)-labeled goat anti-
mouse IgG conjugate (1:80), was added, and the sam-
ples were placed in a 37°C moist chamber for another
hour, and then washed again with PBS. The slides were
sealed with glycerin (glycerin:PBS=1:1), and observed
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by fluorescent microscope (BX51TRF, exposure con-
trol unit PM-20, BH2-RFL-T3; Olympus Optical Co.
Ltd., Tokyo, Japan).
RESULTS
Three of the rabbits died unexpectedly before the sac-
rificing dates and were thus excluded from the study.
Two of them were sent for zootomy to the Veterinary
Hospital, Department of Veterinary Medicine, National
Pingtung University of Science and Technology. Only
middle-sized pulmonary arterial wall hypertrophies
were found in both rabbits, which is a nonspecific
change in rabbits. There was no systemic evidence in
the liver, kidney or brain to suggest that there was any
toxic effect from ET1 (personal communication with
Dr Chang, T.C., D.V.M. & M.S., Chairman, Section of
Veterinary Pathology, Veterinary Hospital, National
Pingtung University of Science and Technology). In
addition, no significant contagion was found in the
rabbits.
Corneal epithelial wound healing 
rate, corneal haze and corneal 
thickness study
The average size of the corneal epithelial defect was
significantly smaller in ET1-treated eyes than in PBS-
treated eyes at 48 and 60 hours (paired t test; Figure
1). All of the corneal epithelial defects were healed in
4 days. The most severe haze did not exceed grade 2
(Table), and there was no significant difference in cor-
neal haze between eyes treated with ET1 and those
treated with PBS (signed rank test; Table). Central
corneal thickness was similar in ET1-treated eyes and
in control eyes on ultrasound pachymetry (p > 0.05,
paired t test and signed rank test).
Immunohistochemistry of corneal
extracellular matrixes
In PBS-treated eyes, anti-collagen type 3 fluorescence
could be found in the subepithelial and superficial
stroma at 7 days. The fluorescence was most promi-
nent at 12 weeks, and remained at 24 weeks. Type 3
collagen fluorescence was most prominent in week 4
in ET1-treated eyes, and fluorescence intensity looked
similar at 4, 12 and 24 weeks. In ET1-treated eyes at
day 7, when compared with PBS-treated eyes, fluo-
rescence of type 3 collagen was more prominent in
the subepithelial and superficial stroma. However, at
week 24, there were no obvious differences between
ET1- and PBS-treated eyes with regard to the fluores-
cence of type 3 collagen.
Anti-collagen type 4 fluorescence was most promi-
nent at day 7 and week 4 in the subepithelial level,
and it gradually decreased at week 12 and week 24 in
PBS-treated eyes. In ET1-treated eyes, type 4 collagen
fluorescence could be found at 7 days, and was most
12
−10
0
10
20
30
40
50
24 36
Hours after laser treatment
48 60 72 84 96E
pi
th
el
ia
l d
ef
ec
t (
m
m
2 )
ET1
PBS
∗
†
Figure 1. Corneal epithelial defect after photorefractive keratec-
tomy. Mean corneal epithelial defect size was smaller in ET1-
treated eyes than in PBS-treated eyes at 48 and 60 hours.
*p = 0.005 (paired t test), ET1-treated eyes (5.8 ± 5.1 mm2) vs.
PBS-treated eyes (7.8 ± 5.6 mm2); †p = 0.018 (paired t test), ET1-
treated eyes (2.7 ± 2.3 mm2) vs. PBS-treated eyes (3.9 ± 3.4 mm2).
Table. Corneal haze after photorefractive keratectomy*†
ET1 PBS
Grade of haze Week Week
2 4 8 12 18 24 2 4 8 12 18 24
0 0 1 2 9 5 5 0 1 3 8 5 5
1 10 10 9 2 8 10 7 3
2 5 4 7 4 1
*Data presented as number of rabbits; †no significant difference between ET1- and PBS-treated eyes (signed rank test). ET1=endothelin-1;
PBS = phosphate-buffered salt solution.
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prominent at 4 weeks. It was not obvious at 12 and 
24 weeks. There was no obvious difference in type 
4 collagen fluorescence between ET1 and control
groups.
In PBS-treated eyes, anti-collagen type 7 fluores-
cence appeared in the subepithelial level at day 7. It was
most prominent at week 4, and gradually decreased at
weeks 12 and 24. Type 7 collagen was found in ET1-
treated eyes at 7 days, was most prominent at 4 weeks,
and gradually decreased at 12 and 24 weeks. There was
no obvious difference between ET1- and PBS-treated
eyes with regard to type 7 collagen fluorescence.
Anti-chondroitin sulfate fluorescence was most
prominent in the subepithelial and superficial stroma
at day 7 in the control group. The fluorescence de-
creased at week 4, and was not obvious at weeks 12
and 24 (Figure 2A). Chondroitin sulfate was most
prominent at day 7. The fluorescence decreased at
week 4, and was almost not visible at week 12 and
week 24 in the ET1 group (Figure 2B). ET1-treated
eyes showed a granular fluorescent pattern in super-
ficial stroma, while PBS-treated eyes showed a band
fluorescent pattern in superficial stroma. At weeks 4,
12 and 24, the anti-chondroitin sulfate fluorescence
was of low strength and showed a similar pattern in
ET1- and PBS-treated eyes.
Anti-fibronectin fluorescence was noted in the sub-
epithelial level at day 7 in PBS-treated eyes. It was
most prominent at week 4 in the subepithelial and
superficial stroma. However, it was not obvious at
weeks 12 and 24 (Figure 3A). In ET1-treated eyes,
anti-fibronectin fluorescence was present at 7 days,
and was most prominent at 4 weeks and 12 weeks. It
decreased at 24 weeks (Figure 3B). The fluorescence
A 
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Figure 2. Immunohistochemistry study of chondroitin sulfate. Bar = 50mm. (A) Anti-chondroitin sulfate fluorescence was most
prominent in the subepithelial and superficial stroma at day 7, decreased at week 4, and was not obvious at weeks 12 and 24 in the 
control group. (B) Chondroitin sulfate was most prominent at day 7, decreased at week 4, and was almost not visible at weeks 12 and
24 in the endothelin-1-treated group.
Kaohsiung J Med Sci May 2008 • Vol 24 • No 5258
Y.H. Lai, H.Z. Wang, C.P. Lin, et al
was about equal at 4 weeks in ET1- and PBS-treated
eyes. However, in ET1-treated eyes, anti-fibronectin
fluorescence lasted at least until week 24 (Figure 3).
DISCUSSION
Both corneal epithelium and stroma are involved in
wound healing after excimer laser treatment. It seems
that the epithelial defect produced by PRK is related
to ocular discomfort and pain [9,10]. Clinically, bandage
contact lenses, topical nonsteroidal anti-inflammatory
drug (NSAID) eye drops or topical steroid eye drops
can be used to relieve the pain [15]. Takagi et al reported
that ET1 promoted the proliferation of corneal epithelial
cells in vitro [7] and increased the healing rate of cor-
neal epithelial wounds in vivo [8]. Although our treat-
ment modality was different from theirs, the present
study confirmed the effect of ET1. In addition, from
this perspective, ET1 may be helpful in decreasing
pain after PRK.
Corneal wound healing responses are mainly in the
stroma [1,16]. After trauma, keratocytes in the wound
bed start to migrate and proliferate [2,16]. They pro-
duce irregularly arrayed collagen and scar tissue,
resulting in corneal haze, which decreases the vision
of patients after operation. In addition, the deposition
of new tissue is associated with corneal stroma re-
thickening, which is related to myopic shift [1,2,17].
Although ET1 has an inhibitory effect on keratocytes
in vitro [11], we found that ET1, 10–7 M five times 
a day for 7 days, could not inhibit central corneal 
re-thickening in rabbits.
Immunohistochemistry studies of corneal extra-
cellular matrixes after PRK without any medication
modulations in monkeys [18,19] and rats [20] have
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Figure 3. Immunohistochemistry study of fibronectin. Bar = 50mm. (A) Anti-fibronectin fluorescence was noted in the subepithelial
level at day 7, was most prominent at week 4 in subepithelial and superficial stroma, and not obvious at weeks 12 and 24 in eyes treated
with phosphate-buffered salt solution. (B) In endothelin-1-treated eyes, anti-fibronectin fluorescence was present at day 7, was most
prominent at weeks 4 and 12, and decreased at week 24.
been reported. Collagen type 3 presents transiently
during the corneal wound healing process and only
in the superficial stroma [18–20]. Our study is in agree-
ment with the above-mentioned reports that corneal
wound healing can last as long as 6 months and type
3 collagen is mainly in the superficial stroma during
the wound healing process [18–20]. Types 4 and 7 col-
lagen are the major components of basement mem-
brane and anchoring fibrils, respectively [19,21]. It is
reasonable that, in our study, they were present in the
subepithelial level, although in different species, the
results of immunohistochemistry study of collagen
types 4 and 7 in the present study and in previous
reports are similar [18–21]. Increased anti-chondroitin
sulfate fluorescence at day 7 and week 4, compared
to week 12 and week 24 were noted in both ET1- and
PBS-treated eyes. The transient increase in the fluo-
rescence of anti-chondroitin sulfate during wound
healing and the presence of it in the superficial stroma
imply that it may be involved in the early stages of
corneal wound healing [22]. However, further inves-
tigation is required to clarify its role in corneal wound
healing.
Fibronectin is involved in cellular migration and
wound healing [18]. It is also present during corneal
wound healing [22–24]. The presence of fibronectin
in the corneal superficial stromal level could last as
long as 4 weeks after PRK [20]. It was proposed that
the fibronectin might be derived from stromal fibro-
blasts for later stages of wound healing [23]. Our results
confirmed the above-mentioned theories. In addition,
we found that ET1 could increase and prolong fi-
bronectin deposition in the superficial stromal levels.
ET1 has been found to have the effect of increasing
fibronectin expression in other tissues [25,26]. If ET1
promotes the migration of corneal epithelial cells via
increasing fibronectin, it requires further study.
One issue we would like to discuss is the duration
of treatment. We performed a preliminary supplemen-
tary study. Two New Zealand white rabbits received
the same experimental setting described above, but
instead of for 1 week, ET1 was applied for 4 weeks.
We found that after 4 weeks of treatment, the corneal
thicknesses in the ET1-treated eyes of the two rabbits
were 87.0% and 95.6%, respectively, of the thick-
nesses before PRK treatment. And in the PBS-treated
eyes of the two rabbits, they were 94.9% and 109.4%,
respectively. Although the sample size is too small to
make any conclusion, these preliminary results might
indicate that ET1 has the effect of inhibiting corneal
re-thickening if an appropriate treatment duration,
such as 1 month, is given.
ET1 can cause vascular remodeling and vascular
hypertrophy [27–29]. Although unexpected death
occurred in three of our rabbits, and hypertrophy of
middle-sized pulmonary arterial walls was found in
two, it is a nonspecific change in rabbits. In addition,
no other evidence was found, in the brain, liver or
kidney, to suggest that there was any systemic toxic
effect from ET1. However, a thorough systemic survey
of ET1 in an animal study is probably needed.
In summary, ET1 10–7 M eye drops five times a day
for 1 week can promote corneal epithelial wound heal-
ing, but it has no effect on corneal haze and corneal
thickness. There was an obvious difference in fibronec-
tin between ET1- and PBS-treated eyes, which implies
that ET1 promotes corneal epithelial wound healing
via increasing the amount of fibronectin.
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